Contemporary Meta-Analysis of Extended Direct Acting Oral Anticoagulant Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
Am J Med. 2020 Mar 06;:
Authors: Bhalla V, Lamping OF, Abdel-Latif A, Bhalla M, Ziada K, Smyth SS
BACKGROUND: Medically ill patients remain at risk of venous thromboembolism for up to 6 weeks after hospital discharge due to factors such as immobilization and inflammation.
METHODS: We conducted a meta-analysis and systematic review of Phase III randomized controlled trials comparing extended use of direct oral anticoagulation (DOAC) post-discharge for venous thromboembolism prophylaxis with placebo.
RESULTS: The primary efficacy outcome (composite of venous thromboembolism and mortality) occurred in 373/13099 patients in the DOAC group (2.9%) and 477/13309 patients in the placebo group (3.6%) with an OR 0.79 (95% CI: 0.69-0.91). The secondary efficacy outcome (non-fatal symptomatic venous thromboembolism) occurred in 75/15573 patients in the DOAC group (0.48%) and 120/15599 in the placebo group (0.77%) with an OR 0.62 (95% CI: 0.47-0.83). The primary safety outcome (major bleeding) occurred in 90/15474 patients in the DOAC group (0.58%) and in 47/15418 patients in the placebo group (0.3%) with an OR 1.92 (95% CI: 1.35-2.73). The secondary safety (clinically relevant non-major bleeding) outcome occurred in 333/15474 patients in the DOAC group (2.2%) and 191/15418 patients in the placebo group (1.2%) with an OR 1.75 (95% CI: 1.46-2.1). The extended use of venous thrombolism prophylaxis post-discharge results in decreased venous thromboembolism events but increased bleeding risk. Our cost-effective analysis of extended DOAC use versus placebo showed superiority of the DOAC group.
CONCLUSION: In conclusion, given the mortality benefit and cost-benefit, extended thromboprophylaxis is a beneficial strategy to efficiently reduce the risk of venous thromboembolism.
PMID: 32151593 [PubMed - as supplied by publisher]